Phase 2, international, multicenter, randomized, open label and parallel group study to evaluate the efficacy and safety of CC-486 (oral azacitidine) alone and in combination with durvalumab (MEDI4736) in subjects with myelodysplastic syndrome who do not achieve a response Objective to treatment with injectable azacitidine or decitabine